Zenas BioPharma Statistics
Total Valuation
Zenas BioPharma has a market cap or net worth of $2.02 billion. The enterprise value is $1.57 billion.
| Market Cap | 2.02B |
| Enterprise Value | 1.57B |
Important Dates
The next estimated earnings date is Thursday, August 13, 2026, before market open.
| Earnings Date | Aug 13, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
Zenas BioPharma has 63.13 million shares outstanding. The number of shares has increased by 107.16% in one year.
| Current Share Class | 63.13M |
| Shares Outstanding | 63.13M |
| Shares Change (YoY) | +107.16% |
| Shares Change (QoQ) | +4.95% |
| Owned by Insiders (%) | 1.57% |
| Owned by Institutions (%) | 75.87% |
| Float | 40.53M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| Forward PS | 55.70 |
| PB Ratio | 6.02 |
| P/TBV Ratio | 6.01 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 11.94, with a Debt / Equity ratio of 0.79.
| Current Ratio | 11.94 |
| Quick Ratio | 11.74 |
| Debt / Equity | 0.79 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -30.31 |
Financial Efficiency
Return on equity (ROE) is -137.11% and return on invested capital (ROIC) is -35.38%.
| Return on Equity (ROE) | -137.11% |
| Return on Assets (ROA) | -29.06% |
| Return on Invested Capital (ROIC) | -35.38% |
| Return on Capital Employed (ROCE) | -61.63% |
| Weighted Average Cost of Capital (WACC) | n/a |
| Revenue Per Employee | n/a |
| Profits Per Employee | -$2.55M |
| Employee Count | 167 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
In the past 12 months, Zenas BioPharma has paid $126,000 in taxes.
| Income Tax | 126,000 |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +119.89% in the last 52 weeks.
| Beta (5Y) | n/a |
| 52-Week Price Change | +119.89% |
| 50-Day Moving Average | 25.70 |
| 200-Day Moving Average | 25.93 |
| Relative Strength Index (RSI) | 61.83 |
| Average Volume (20 Days) | 681,514 |
Short Selling Information
The latest short interest is 12.17 million, so 19.28% of the outstanding shares have been sold short.
| Short Interest | 12.17M |
| Short Previous Month | 12.20M |
| Short % of Shares Out | 19.28% |
| Short % of Float | 30.03% |
| Short Ratio (days to cover) | 11.05 |
Income Statement
| Revenue | n/a |
| Gross Profit | -193.59M |
| Operating Income | -251.41M |
| Pretax Income | -425.03M |
| Net Income | -425.15M |
| EBITDA | -423.04M |
| EBIT | -423.08M |
| Earnings Per Share (EPS) | -$8.82 |
Balance Sheet
The company has $717.21 million in cash and $266.83 million in debt, with a net cash position of $450.38 million or $7.13 per share.
| Cash & Cash Equivalents | 717.21M |
| Total Debt | 266.83M |
| Net Cash | 450.38M |
| Net Cash Per Share | $7.13 |
| Equity (Book Value) | 335.83M |
| Book Value Per Share | 5.38 |
| Working Capital | 669.00M |
Cash Flow
In the last 12 months, operating cash flow was -$210.48 million and capital expenditures -$2,000, giving a free cash flow of -$210.48 million.
| Operating Cash Flow | -210.48M |
| Capital Expenditures | -2,000 |
| Depreciation & Amortization | 39,000 |
| Net Borrowing | 267.50M |
| Free Cash Flow | -210.48M |
| FCF Per Share | -$3.33 |
Margins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
Zenas BioPharma does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -107.16% |
| Shareholder Yield | -107.16% |
| Earnings Yield | -21.05% |
| FCF Yield | -10.42% |
Analyst Forecast
The average price target for Zenas BioPharma is $43.50, which is 35.98% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $43.50 |
| Price Target Difference | 35.98% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 8 |
| Revenue Growth Forecast (3Y) | 136.99% |
| EPS Growth Forecast (3Y) | n/a |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
Zenas BioPharma has an Altman Z-Score of -0.15 and a Piotroski F-Score of 2. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -0.15 |
| Piotroski F-Score | 2 |